Results 61 to 70 of about 1,055,250 (236)

How Can We Personalize the Delivery of Onabotulinumtoxin‐A for Patients With Neurogenic Lower Urinary Tract Dysfunction?

Neurourology and Urodynamics, EarlyView.
ABSTRACT Background & Aims Neurogenic lower urinary tract dysfunction (NLUTD) can produce bothersome urinary symptoms, impact quality of life, and in some cases, lead to deterioration of upper urinary tract function. Intradetrusor injection of onabotulinumtoxin‐A (BoNT‐A) is approved for NLUTD in patients who have an inadequate response to or ...
Shirley L. Wang, William I. Jaffe, Ariana L. Smith   +2 more
wiley   +1 more source

Comedication and Treatment Length in Users of Acetylcholinesterase Inhibitors

Dementia and Geriatric Cognitive Disorders Extra, 2017
Background/Aims: Reduced clinical effect on cognitive decline in dementia by acetylcholinesterase inhibitors (AChEIs) may be due to concurrent use of drugs with anticholinergic properties.
Anne Sverdrup Efjestad, Hege Ihle-Hansen, Vidar Hjellvik, Hege Salvesen Blix   +3 more
doaj   +1 more source

Mirabegron and Intradetrusor Onabotulinumtoxina for Overactive Bladder in Parkinson's Disease: A Systematic Review and Meta‐Analysis

Neurourology and Urodynamics, EarlyView.
ABSTRACT Objective To synthesize the evidence on the efficacy and safety of mirabegron and intradetrusor onabotulinumtoxinA (BoNT‐A) as separate interventions for overactive bladder (OAB) in Parkinson's disease (PD). Methods A systematic review and meta‐analysis with parallel synthesis of two distinct interventions was conducted of randomized and ...
Hussain Arshad, Raiyana Nuha, Shehab Khashaba, David Gillatt, Simon J. G. Lewis   +4 more
wiley   +1 more source

Urodynamic Voiding Patterns in Multiple Sclerosis

Neurourology and Urodynamics, EarlyView.
ABSTRACT Aims This study aimed to describe urodynamic voiding patterns in patients with MS (PwMS) using standardized assessments, and to compare the performance of the available nomograms and indices for obstruction and bladder contractility. Methods PwMS and lower urinary tract symptoms underwent cystometry and pressure flow studies.
Camille Chesnel, Nicolas Turmel, Maelys Teng, Emilie Blouet, Gérard Amarenco, Claire Hentzen   +5 more
wiley   +1 more source

Anticholinergic burden in adult and elderly people with intellectual disabilities: Results from an Italian multicenter cross-sectional study. [PDF]

PLoS ONE, 2018
BACKGROUND:Adults and older people with intellectual disabilities (ID) frequently receive anti-cholinergic drugs in chronic use, but no studies in Italy to date have investigated cumulative anticholinergic exposure and factors associated with high ...
Luc Pieter De Vreese, Ulrico Mantesso, Elisa De Bastiani, Annachiara Marangoni, Elisabeth Weger, Tiziano Gomiero   +5 more
doaj   +1 more source

The Benefits of Adding Non‐Antimuscarinic Pharmaceuticals in Combination With Beta‐3 Agonists for Overactive Bladder Treatment: A Systematic Review

Neurourology and Urodynamics, EarlyView.
ABSTRACT Introduction Antimuscarinics, as the current first‐line pharmacologic therapies for overactive bladder, exhibit low patient adherence and high rates of reported side effects. As a modern alternative pharmaceutical treatment, beta‐3 agonists, which relax the urinary bladder, may be more tolerable for patients, increasing adherence and ...
Felicity Smith, Charlotte Phelps, Christian Moro   +2 more
wiley   +1 more source

Predictors of 2‐Week Post‐Void Residual After Intradetrusor OnabotulinumtoxinA Injection for Overactive Bladder: A Sex‐ and Neurogenic Status‐Stratified Analysis

Neurourology and Urodynamics, EarlyView.
ABSTRACT Objective Urinary retention rates after intradetrusor onabotulinumtoxinA (BTX‐A) peak at 2 weeks, yet risk stratification by sex and neurogenic status remains limited. We evaluated predictors of 2‐week post‐void residual (PVR) and differences by sex and neurogenic bladder status using the largest retrospective cohort to date.
Saawan D. Patel, Evan Rosario, Ariana L. Smith   +2 more
wiley   +1 more source

Association of anticholinergic cognitive load with the appointment of potentially not recommended drugs and the frequency of hospitalization of elderly and senile patients

Качественная клиническая практика, 2019
Actuality. The pharmacotherapy practice in elderly and senile patients is characterized by a widespread use of drugs with anticholinergic properties. Available data indicate that the combined anticholinergic cognitive burden correlates with the risk of ...
A. M. Al-Rajawi, S. K. Zyryanov, E. A. Ushkalova, O. I. Butranova, A. P. Pereverzev   +4 more
doaj   +1 more source

Botulinum toxin use in patients with neurological disorders: A U.S.‐based claims database analysis

PM&R, EarlyView.
Abstract Background and Objective Real‐world evidence describing long‐term persistency with botulinum toxin (BoNT) therapy is limited. We assessed treatment patterns and persistency with BoNT in clinical practice over 2 years. Design Retrospective, longitudinal, claims database analysis. Setting Medical claims data from the Merative MarketScan database
David M. Simpson, Jonathan Bouchard, Simon Page, Seth Goldfarb, Atul T. Patel   +4 more
wiley   +1 more source

Nationwide trends in psychiatric prescription practices for drugs with putative cognitive adverse effects in schizophrenia spectrum and bipolar disorders from 2013 to 2022

Journal of Pharmaceutical Policy and Practice
Background The management of schizophrenia spectrum (SZ) and bipolar disorders (BD) can involve psychotropic polypharmacy, high psychotropic doses, a high anticholinergic burden, and the use of anticholinergic agents and benzodiazepines, which are ...
Nathan Vidal, Solène Frileux, Nadia Younès, Emmanuelle Corruble, Christine Passerieux, Eric Brunet-Gouet, Paul Roux   +6 more
doaj   +1 more source